U.S.
  Securities and Exchange Commission

Washington,
  D. C. 20549

FORM
  10-KSB/A

Amendment No. 1



|x | ANNUAL
        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
        OF 1934For the fiscal year ended - June 30, 2005
|- | ---------------------------------------------------------------------------------------------------------------------------------------------
|  | OR                                                                                                                                           
|o | TRANSITION
        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
        OF 1934For the transition period from       

Commission
  file number 000-33191



VISUALMED
  CLINICAL SOLUTIONS CORP.

(Name
  of small business issuer in its charter)



| | NEVADA(State or other jurisdiction of incorporation or organization) |  | 88-0436055(I.R.S. Employer Identification No.) | 
| | -------------------------------------------------------------------- |  | ---------------------------------------------- | 

1035
  Laurier St. West

Suite
  200

Montreal,
  Quebec

Canada
  H2V 2L1

(Address
  of principal executive offices) (Zip Code)



(514)
  274-1115

Issuers
  telephone number

Securities
  registered pursuant to Section 12(b) of the Exchange Act:



| | Title
        of each class: |  | Name
        of each exchange on which registered:
| | ---------------------------- |  | --------------------------------------------------
| | None                         |  | None                                              

Securities
  registered pursuant to Section 12(g) of the Exchange Act:

Common
  Stock

42,381,400
  Common Shares

Check
  whether the issuer is not required to file reports pursuant to Section 13 or
  15(d) of the Exchange

Act.o

Check
  whether the issuer (1) filed all reports required to be filed by Section 13
  or 15(d) of the Exchange Act during the past 12 months (or for such shorter
  period that the registrant was required to file such reports) and (2) has been
  subject to such filing requirements for the past 90 days.

| | Yesx |  | Noo | 
| | ---- |  | --- | 



---



Check
  if there is no disclosure of delinquent filers in response to Item 405 of Regulation
  S-B contained in this form, and no disclosure will be contained, to the best
  of registrants knowledge, in definitive proxy or information statements
  incorporated by reference in Part III of this Form 10-KSB or any amendment to
  this Form 10-KSB.o

Indicate
  by check mark whether the registrant is a shell company (as defined in Rule
  12-b-2 of the Exchange Act).

| | Yeso |  | Nox | 
| | ---- |  | --- | 

State
  issuers revenues for its most recent fiscal year. None

The
  aggregate market value of the voting and non-voting common equity held by non-affiliates,
  computed by reference to the average bid and asked price of such common equity
  as of June 30, 2005 was $24,664,190.

As
  of September 28, 2005, the issuer had 44,833,634 outstanding shares of
  common stock.

Transitional
  Small Business Disclosure Format (Check one):

| | Yeso |  | Nox | 
| | ---- |  | --- | 

DOCUMENTS
  INCORPORATED BY REFERENCE: None








---



Explanatory Note



This Amendment on Form 10-KSB/A (Amendment No. 1) is being filed to amend and restate in its entirety Part II, Item 6 and Item 7 of the Annual Report on Form 10-KSB for the fiscal year ended June 30, 2005 of VisualMed Clinical Solutions Corp. as initially filed with the Securities and Exchange Commission on filed on September 29, 2005 (the Original 10-KSB). This Amendment No. 1 does not otherwise alter the disclosures set forth in the Original 10-KSB, and does not reflect events occurring after the filing of the Original 10-KSB. This Amendment No. 1 is effective for all purposes as of the date of the filing of the Original 10-KSB.



TABLE
  OF CONTENTS



|                |   |                                                                   |  |    
|--------------- | - | ----------------------------------------------------------------- |  | ---
|PART
        II | 1
|                |   |                                                                   |  |    
|ITEM
        6. |   | MANAGEMENTS
        DISCUSSION AND ANALYSIS OR PLAN OF OPERATION |  | 1  
|                |   |                                                                   |  |    
|ITEM
        7. |   | FINANCIAL
        STATEMENTS                                      |  | F-1
|                |   |                                                                   |  |    





i



---





|ITEM
        6. | MANAGEMENTS
        DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
|--------------- | ------------------------------------------------------------------

Overview

It
  is important to note that our business changed dramatically on October 13, 2004,
  when we ceased our mining and exploration activities and entered the field of
  developing and marketing clinical information systems. We refer to the twelve
  month period ended June 30, 2005, as fiscal 2005, and the twelve month period
  ended June30, 2004, as
  fiscal 2004.

We
  had $348,410 of cash at June 30, 2005 and no revenue for fiscal 2005. These
  factors raise substantial doubt about our ability to continue as a going concern
  without raising significant additional capital.

We
  incurred losses of $6,301,451 for fiscal 2005 as compared to losses of $9,204
  in fiscal 2004. The principal component of these losses was the one-time start-up
  costs that we incurred with respect to our entry to a new field of business
  following the Acquisition. These costs included the costs associated with the
  establishment of a world-wide, state-of-the-art service center capable of supporting
  our customers by remote support technology. Also, as part of the new marketing
  effort, there was a considerable amount of effort put into presentation and
  hospital-specific infrastructure configurations in order to respond to major
  tenders and requests from potential buyers. Significant expenses equally went
  into hiring marketing employees and consultants. We also incurred professional
  expenses, depreciation and filing fees.

Operating
  expenses for fiscal 2005 were $1,766,026, consisting of customer service expense
  of $429,010, depreciation expense of $4,156, development costs of $561,356,
  general and administrative expense of $687,293 and sales and marketing expenses
  of $83,611. We also incurred financing costs of $4,514,285.

At
  June 30, 2005, we had pre-paid expenses of $454,777. This amount consisted of
  a partial pre-payment of property taxes in the amount of $5,836, payment of
  a retainer for legal services to Hovington Pellerin Inc. in the amount of $21,007
  and an advance in the amount of $427,934 to Medicool Health Systems Inc., an
  unaffiliated company and key supplier of technical services to us (Medicool).
  The advance to Medicool was made to ensure that a series of strategic technical
  services that Medicool was contracted to provide us would be available in a
  timely fashion by affording Medicool the resources to maintain a staff of technical
  specialists required to make certain modifications to our products. As a result
  of having the benefit of Medicools services, we should be able to better,
  and more efficiently, customize our products and respond to particular client
  needs (including at their initial requests for proposals) which may have a positive
  impact on our financial condition and future result of operations.





1



---



Marketing
  Strategy and Plan of Operations

The
  main challenges that we will have to meet over the next 12 months will continue
  to be the funding of our operations, the sales and marketing of our modules
  and the conclusion of strategic alliances to help us penetrate specific marketplaces
  in promising geographies. Since the Acquisition, we have developed a comprehensive
  marketing organization that can handle market survey, develop marketing tools
  and support the sales funnel we have built which currently includes more than
  50 potential client hospitals. We will continue to hire sales and marketing
  executives and consultants as our customer base continues to grow.

The
  services of Mr. Andre G. Nadeau, a leading marketing consultant, were retained
  in fiscal 2005 in order to manage our marketing operations, and to build a dynamic
  marketing department with the following significant early results: the full
  VisualMED system is slated to go live at Southwest Regional Rehabilitation Center
  of Battle Creek, MI, in October 2005. Southwest Regional is a small healthcare
  facility specializing in rehabilitation, and the contract calls for hospital-wide
  implementation of the VisualMED system by September 2006. Additionally, our
  sales funnel has expanded rapidly as the market prepares for a large scale move
  to information technology solutions to healthcare issues.

A
  new board of advisors was created in April 2005 to help us create a better marketing
  strategy and to help tailor our sales approach to evolving market realities.
  We expect this initiative will help support our sales and marketing department,
  bringing together experts from the medical and international business community.
  Among key members of the board of advisers are Mr. Andre G. Nadeau, Mr. Christian
  Chagnon of I.U.G.O. Ventures, one of Canadas largest private venture capital
  funds, Mr. Jean Rouleau, Dean of the University of Montreals Faculty
  of Medicine, and Dr. Todd McConnell, Physician in Chief at St. Marys
  Hospital of Montreal.

In
  March 2005, we have also signed a cooperative agreement with engineering firm
  SNC Lavalin of Montreal, Canada. One of the worlds largest publicly traded
  engineering firms; SNC Lavalin brings expertise in project management, hospital
  construction and management, as well as automation. The arrangement is designed
  to expand the scope of our delivery capabilities.

Our
  general corporate strategy will be to build on recent successful implementation
  contracts in North America, and to work toward our short-term goal of having
  the full VisualMED system deployed in at least 12 hospitals by calendar year
  end 2006. Management is confident that a 12-hospital base would constitute a
  threshold for both market credibility and long-term profitability.

We
  intend to target markets where current legal regulations encourage the adoption
  of our clinical management modules. We will aggressively pursue these markets
  through the creation of sales consortiums that bring together local healthcare
  consultants, hardware vendors and local systems integrators. We are significantly
  advanced in creating one such consortium in France that will pursue opportunities
  offered by new French legislation that has mandated the implementation throughout
  the French healthcare system of a universal Electronic Medical Record. An agreement
  has been reached for a first pilot implementation in one of the countries largest
  hospitals. In Italy, we have begun to leverage some of our local relationships
  into creating a sales funnel of more than six hospitals. In the Netherlands,
  we are in negotiations with a Dutch medical supply company for a distributorship
  agreement. Despite typically long sales cycle, we expect concrete results before
  the calendar year end. We are continuing to build alliances in other European
  markets. We will make a special effort in the Canadian market, where the federal
  government is preparing to legalize e-Prescriptions in an effort to contain
  the rising cost of prescription drugs. Finally, we will take advantage of the
  construction of new state of the art hospital facilities in developing countries
  such as Tunisia that provide elective surgery to European patients.

In
  order to continue financing our operations, we are currently negotiating a private
  placement. The proceeds of this financing, if consummated, are expected to provide
  sufficient liquidity for the next 12 months. We cannot assure you that we will
  complete a private placement on favorable terms or at all or whether financing
  will be available to us from other sources in the future.





2



---



Subsequent
  Events

Since
  June 30, 2005, we have concluded an agreement to implement the full VisualMED
  system at Kansas Surgery Hospital of Wichita, Kansas. The implementation has
  begun, the hardware has been purchased and is currently being installed.

Financial
  Condition, Liquidity and Capital Resources

At
  June 30, 2005, all of our principal capital resources have been acquired through
  the issuance of our common stock and advances from our investors. Cash used
  in operations was $1,947,200 for fiscal 2005.

At
  June 30, 2005, we had a negative working capital of $49,345 compared to a deficiency
  of $20,982 at June 30, 2004. We had cash on hand of $348,410 at June 30, 2005.
  We had a net loss of $6,301,451 for fiscal 2005 and $9,204 for fiscal 2004.
  At June 30, 2005, our total assets were $908,354 as compared to $1,616 at June
  30, 2004. At June 30, 2005, our total liabilities increased to $930,824 from
  $21,674 at June 30, 2004.

We
  will need to raise additional equity/debt financing to sustain operations over
  the next 12 months. Our auditors have expressed substantial doubt about our
  ability to continue as a going concern in their audit report.

Critical
  Accounting Policies

Our
  discussion and analysis of financial condition and results of operations are
  based upon the financial statements, which have been prepared in accordance
  with accounting principles generally accepted in the United States of America.
  The preparation of financial statements require management to make estimates
  and judgments that affect the reported amounts of assets and liabilities, revenues
  and expenses and disclosures on the date of the financial statements. On an
  on-going basis, we evaluate our estimates, including, but not limited to, those
  related to revenue recognition.

We
  use authoritative pronouncements, historical experience and other assumptions
  as the basis for making judgments. Actual results could differ from those estimates.
  Critical accounting policies identified are as follows:

Long-Lived
  Assets

In
  accordance with SFAS No. 144, Accounting for the Impairment or Disposal
  of Long-Lived Assets, we test long-lived assets or asset groups for recoverability
  when events or changes in circumstances indicate that their carrying amount
  may not be recoverable. Circumstances which could trigger a review include,
  but are not limited to: significant decreases in the market price of the asset;
  significant adverse changes in the business climate or legal factors; accumulation
  of costs significantly in excess of the amount originally expected for the acquisition
  or construction of the asset; current period cash flow or operating losses combined
  with a history of losses or a forecast of continuing losses associated with
  the use of the asset; and current expectation that the asset will more likely
  than not be sold or disposed significantly before the end of its estimated useful
  life.

Recoverability
  is assessed based on the carrying amount of the asset and its fair value which
  is generally determined based on the sum of the undiscounted cash flows expected
  to result from the use and the eventual disposal of the asset, as well as specific
  appraisal in certain instances. An impairment loss is recognized when the carrying
  amount is not recoverable and exceeds fair value.

Foreign
  Currency Transactions/Balances

Our
  functional and reporting currency is the United States dollar. The functional
  currency of our subsidiary is the Canadian dollar. The financial statements
  of the subsidiary are translated to United States dollars in accordance with
  SFAS No. 52 Foreign Currency Translation using period-end rates
  of exchange for assets and liabilities, and average rates of exchange for the
  period for revenues and expenses. Translation gains (losses) are recorded in
  accumulated other comprehensive income (loss) as a component of stockholders
  equity. Foreign currency transaction gains and losses are included in current
  operations.





3



---



Stock-Based
  Compensation

We
  have elected to apply the intrinsic value method of accounting in accordance
  with Accounting Principles Board Opinion No. 25, Accounting for Stock
  Issued to Employees (APB 25). Under the intrinsic value method of
  accounting, compensation expense is recognized if the exercise price of the
  our employee stock options is less than the market price of the underlying common
  stock on the date of grant. Stock-based compensation for employees is recognized
  on the straight-line basis over the vesting period of the individual options.
  Stock options granted to non-employees are accounted for under Statement of
  Financial Accounting Standards No. 123 Accounting for Stock-Based Compensation
  (SFAS 123), which establishes a fair value based method of accounting for stock-based
  awards, and recognizes compensation expense based on the fair value of the stock
  award or fair value of the goods and services received, whichever is more reliably
  measurable. Under the provisions of SFAS 123, companies that elect to account
  for stock-based awards in accordance with the provisions of APB 25 are required
  to disclose the pro forma net income (loss) that would have resulted from the
  use of the fair value based method under SFAS 123.

Revenue
  Recognition

We
  recognize revenue in accordance with Securities and Exchange Commission Staff
  Accounting Bulletin No. 104 (SAB 104), Revenue Recognition in Financial
  Statements. Revenue is recognized only when the price is fixed or determinable,
  persuasive evidence of an arrangement exists, the service is performed, and
  collectibility is reasonably assured.

We
  continually monitor timely payments and assess any collection issues. The allowance
  for doubtful accounts is based on our detailed assessment of the collectibility
  of specific customer accounts. Any significant customer accounts that are not
  expected to be collected are excluded from revenues.

Development
  Costs

Costs
  related to the enhancement of existing medical software modules are expensed
  as incurred until technological feasibility in the form of a working model has
  been established. The time period between the establishment of technological
  feasibility and completion of product development is expected to be short, therefore
  the Company has not capitalized any product development costs during the period.

Disclosure Regarding Forward-Looking Statements

Certain
  statements contained in this annual report on Form 10KSB/A constitute
  forward-looking statements within the meaning of Section 21E of the Securities
  Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995.
  Such forward-looking statements involve known and unknown risks, uncertainties
  and other factors which may cause deviations in actual results, performance
  or achievements to be materially different from any future results, performance
  or achievement expressed or implied. Such factors include but are not limited
  to: market and customer acceptance of and satisfaction with our products, market
  demand for our products; fluctuations in foreign currency markets; the use of
  estimates in the preparation of our financial statements; the impact of competitive
  products and pricing in our field; the ability to develop and launch new products
  in a timely fashion; government and industry regulatory environment; fluctuations
  in operating results, including, but not limited to, spending on research and
  development, spending on sales and marketing activities, spending on technical
  and product support; and other risks outlined in previous filings with the Securities
  and Exchange Commission, and in this annual report on Form 10-KSB/A. The
  words believe, expect, anticipate, may,
  intend and plan and similar expressions identify forward-looking
  statements. Such statements are subject to risks and uncertainties that cannot
  be quantified and, consequently, actual results may differ materially from those
  expressed or implied by such forward-looking statements. You are cautioned not
  to place undue reliance on these forward-looking statements. The terms Company,
  we, us, our, VisualMED and the
  Registrant refer to VisualMED Clinical Solutions Corp., a Nevada corporation,
  and its subsidiaries. Factors that could cause actual results to differ from
  those expressed in forward-looking statements include, but are not limited to:

| |  | Our limited operating history;
| | - | ------------------------------

| |  | Our auditors have issued a going concern opinion. Therefore we may not be able to achieve our objectives and may have to suspend or cease operations;
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Because we have historically incurred losses and these losses may increase in the future, we must begin generating a profit from our operations. If we do not begin generating a profit we may have to suspend or cease operations;
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | We have experienced a history of losses and expect to incur future losses. Therefore, we must continue to raise money from investors to fund our operations. If we are unable to fund our operations, we will cease doing business;                                                                        
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | Because
        we depend on a limited number of third parties to manufacture and supply
        critical components for our products and services, if the third party
        manufacturer should cease operations or refuse to sell components to us,
        we may have to suspend or cease operations;

| |  | If
        we cannot deliver the VisualMed systems our customers demand, we will
        be unable to attract customers, which would likely result in a loss of
        income and eventually a termination of our operations;
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Competition from companies with already established marketing links to our potential customers may adversely affect our ability to market our products;
| | - | -------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Our parent company has significant influence over our corporate decisions;
| | - | --------------------------------------------------------------------------

| |  | Because
        we do not have any patents, we rely on trade secrets, confidentiality
        agreements and contractual agreements, which may not be adequate to protect
        our proprietary interests. If our proprietary interests are divulged to
        the public, our operations may be adversely impacted and we may have to
        cease operations;
| | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | We may be exposed to liability claims if products based on our technologies are marketed and sold. We have liability insurance coverage in the amount of $1,000,000, however, if a judgment is rendered against us in excess of the amount of our coverage, we may have to cease operations;
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Third parties may claim that our current or future products or services infringe their proprietary rights or assert other claims against us;
| | - | --------------------------------------------------------------------------------------------------------------------------------------------

| |  | Fluctuations in the value of foreign currencies could result in increased product costs and operating expenses;
| | - | ---------------------------------------------------------------------------------------------------------------

| |  | We must be able to respond to rapidly changing technology, services and standards in order to remain competitive;
| | - | -----------------------------------------------------------------------------------------------------------------

| |  | Because the market for our common stock is limited, our investors may not be able to resell their shares of common stock;
| | - | -------------------------------------------------------------------------------------------------------------------------

| |  | Because our common stock is subject to penny stock rules, the liquidity of investments may be restricted.
| | - | ---------------------------------------------------------------------------------------------------------

4



---



VisualMED Clinical Solutions Corp.
  (formerly Ancona Mining Corporation)
  (A Development Stage Company)

June 30, 2005

|                                                         |      
|-------------------------------------------------------- | -----
|                                                         | Index
|                                                         |      
|Report of Independent Registered Public Accounting Firm  | F1  
|                                                         |      
|Consolidated Balance Sheets                              | F2  
|                                                         |      
|Consolidated Statements of Operations                    | F3  
|                                                         |      
|Consolidated Statements of Cash Flows                    | F4  
|                                                         |      
|Consolidated Statement of Stockholders Equity (Deficit) | F5  
|                                                         |      
|Consolidated Notes to the Financial Statements           | F6  

---



|                                                                    |                                                                     
|------------------------------------------------------------------- | --------------------------------------------------------------------
|(MANNING ELLIOTT LOGO)                                             
|                                                                   
|                                                                   
|(MANNING ELLIOTT LOGO)                                              | 11th
  floor, 1050 West Pender Street, Vancouver, BC, Canada V6E 3S7
|                                                                   
|Phone:
  604. 714. 3600 Fax: 604. 714. 3669 Web: manningelliott.com

Report of Independent Registered Public Accounting Firm

To the Stockholders and Directors
of VisualMED Clinical Solutions Corp.
(formerly Ancona Mining
Corporation)(A Development Stage Company)

We have audited the accompanying consolidated
balance sheets of VisualMED Clinical Solutions Corp. (formerly Ancona Mining
Corporation) (A Development Stage Company) as of June 30, 2005 and 2004 and the
related consolidated statements of operations, cash flows and stockholders
deficit for the period from September 7, 1999 (Date of Inception) to June 30,
2005 and for each of the years in the two year period ended June 30, 2005.
These financial statements are the responsibility of the Companys management.
Our responsibility is to express an opinion on these financial statements based
on our audits.

We conducted
our audits in accordance with the Standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

In our opinion, the aforementioned
consolidated financial statements present fairly, in all material respects, the
financial position of VisualMED Clinical Solutions Corp. (A Development Stage
Company) as of June 30, 2005 and 2004, and the results of its operations and
its cash flows for the period from September 1, 1999 (Date of Inception) to
June 30, 2005 and for each of the years in the two year period ended June 30,
2005, in conformity with accounting principles generally accepted in the United
States.

The accompanying consolidated financial
statements have been prepared assuming the Company will continue as a going
concern. As discussed in Note 1 to the financial statements, the Company has
not generated any revenue and has accumulated operating losses. These factors
raise substantial doubt about the Companys ability to continue as a going
concern. Managements plans in regard to these matters are also discussed in
Note 1. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

/s/ Manning Elliott

CHARTERED ACCOUNTANTS

Vancouver, Canada

August 26, 2005

F-1

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)Consolidated Balance Sheets
(expressed in U.S. dollars)

|                                                                        |  |                     |            |                     |  |         
|----------------------------------------------------------------------- |  | ------------------- | ---------- | ------------------- |  | --------
|                                                                        |  | June 30,
  2005
  $ |            | June 30,
  2004
  $ | 
|                                                                        |  |                     |            |                     |  |         
|Assets                                                                  |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Current
  Assets                                                        |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Cash                                                                    |  |                     | 348,410    |                     |  | 692     
|Advances to related parties (Notes 3 and
8)                             |  |                     | 57,265     |                     |  |        
|Prepaid expenses                                                        |  |                     | 454,777    |                     |  |        
|Other assets                                                            |  |                     | 14,512     |                     |  |        
|                                                                        |  |                     |            |                     |  |         
|Total
  Current Assets                                                  |  |                     | 874,964    |                     |  | 692     
|                                                                        |  |                     |            |                     |  |         
|Property and
  Equipment (Note 4)                                       |  |                     | 33,390     |                     |  | 924     
|                                                                        |  |                     |            |                     |  |         
|Total Assets                                                            |  |                     | 908,354    |                     |  | 1,616   
|                                                                        |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Liabilities
  and Stockholders Equity (Deficit)                        |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Current
  Liabilities                                                   |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Accounts payable                                                        |  |                     | 96,850     |                     |  | 3,655   
|Accrued liabilities                                                     |  |                     | 105,350    |                     |  | 5,800   
|Notes payable (Note 6)                                                  |  |                     | 651,865    |                     |  |        
|Advances from related party (Note 8)                                    |  |                     |           |                     |  | 12,219  
|Current portion of capital lease obligation
  (Note 7)                  |  |                     | 3,244      |                     |  |        
|Deferred revenue                                                        |  |                     | 67,000     |                     |  |        
|                                                                        |  |                     |            |                     |  |         
|Total
  Current Liabilities                                             |  |                     | 924,309    |                     |  | 21,674  
|                                                                        |  |                     |            |                     |  |         
|Capital
  Lease Obligation (Note 7)                                     |  |                     | 6,515      |                     |  |        
|                                                                        |  |                     |            |                     |  |         
|Total
  Liabilities                                                     |  |                     | 930,824    |                     |  | 21,674  
|                                                                        |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Commitments
  (Notes 1 and 11)                                          |  |                     |            |                     |  |         
|                                                                        |  |                     |            |                     |  |         
|Stockholders
  Equity (Deficit)                                        |  |                     |            |                     |  |         
|Common Stock,                                                           |  |                     |            |                     |  |         
|100,000,000 shares authorized with a par
  value of $0.00001;           |  |                     |            |                     |  |         
|42,381,400 and 45,466,500 shares
  issued and outstanding, respectively |  |                     | 424        |                     |  | 455     
|Additional
  Paid-in Capital                                            |  |                     | 6,687,006  |                     |  | 380,765 
|Accumulated
  Other Comprehensive Loss                                  |  |                     | (7,171     | )                   |  |        
|Deficit
  Accumulated During the Development Stage                      |  |                     | (6,702,729 | )                   |  | (401,278
|                                                                        |  |                     |            |                     |  |         
|Total
  Stockholders Equity (Deficit)                                  |  |                     | (22,470    | )                   |  | (20,058 
|                                                                        |  |                     |            |                     |  |         
|Total
  Liabilities and Stockholders Equity (Deficit)                  |  |                     | 908,354    |                     |  | 1,616   
|                                                                        |  |                     |            |                     |  |         

(The accompanying notes are an integral part of these consolidated financial statements)

F-2

---



VisualMED Clinical Solutions
Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)Consolidated Statements of Operations
(expressed in U.S. dollars)

|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|------------------------------------------------------ |  | ------------------------------------------------------------------------------------- | ---------- | ------------------------------------------ |  | ------------------------------------------ | - |  | ---------- | -
|                                                       |  | Accumulated
  from
  September 7, 1999
  (Date of Inception)
  to June 30,
  2005
  $ |            | For the
  Year Ended
  June 30,
  2005
  $ |  | For the
  Year Ended
  June 30,
  2004
  $ |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |  
|Revenue                                                |  |                                                                                       |           |                                            |  |                                           |   |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Expenses                                               |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Customer service                                       |  |                                                                                       | 429,010    |                                            |  | 429,010                                    |   |  |           |  
|Depreciation                                           |  |                                                                                       | 4,756      |                                            |  | 4,756                                      |   |  |           |  
|Development costs                                      |  |                                                                                       | 561,356    |                                            |  | 561,356                                    |   |  |           |  
|General and administration                             |  |                                                                                       | 687,293    |                                            |  | 687,293                                    |   |  |           |  
|Sales and marketing                                    |  |                                                                                       | 83,611     |                                            |  | 83,611                                     |   |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Total
  Expenses                                       |  |                                                                                       | 1,766,026  |                                            |  | 1,766,026                                  |   |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Net Loss
  From Operations                             |  |                                                                                       | (1,766,026 | )                                          |  | (1,766,026                                 | ) |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Other Income
  (Expenses):                             |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Interest expense                                       |  |                                                                                       | (39,718    | )                                          |  | (39,718                                    | ) |  |           |  
|Financing costs (Note 9(d) and (e))                    |  |                                                                                       | (4,514,285 | )                                          |  | (4,514,285                                 | ) |  |           |  
|Foreign exchange gain                                  |  |                                                                                       | 7,032      |                                            |  | 7,032                                      |   |  |           |  
|Gain on forgiveness of debt                            |  |                                                                                       | 12,689     |                                            |  | 12,689                                     |   |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Net Loss
  Before Discontinued Operations              |  |                                                                                       | (6,300,308 | )                                          |  | (6,300,308                                 | ) |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Discontinued
  Operations                              |  |                                                                                       | (402,421   | )                                          |  | (1,143                                     | ) |  | (9,204     | )
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Net Loss for
  the Period                              |  |                                                                                       | (6,702,729 | )                                          |  | (6,301,451                                 | ) |  | (9,204     | )
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Other
  Comprehensive Loss                             |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Foreign currency translation adjustments               |  |                                                                                       | (7,171     | )                                          |  | (7,171                                     | ) |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Comprehensive
  Loss                                   |  |                                                                                       | (6,709,900 | )                                          |  | (6,308,622                                 | ) |  | (9,204     | )
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Net Loss Per
  Share  Basic and Diluted               |  |                                                                                       |            |                                            |  | (0.15                                      | ) |  |           |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  
|Weighted
  Average Shares Outstanding (split-adjusted) |  |                                                                                       |            |                                            |  | 42,140,000                                 |   |  | 45,467,000 |  
|                                                       |  |                                                                                       |            |                                            |  |                                            |   |  |            |  

(The accompanying notes are an integral part
of these consolidated financial statements)

F-3

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)Consolidated Statements of Cash Flows
(expressed in U.S. dollars)

|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|------------------------------------------------------------------------------- |  |  | ------------------------------------------------------------------------------------- | - | -------------------------------------------- | ---------- | -------------------------------------------- |  | ------ | -
|                                                                                |  |  | Accumulated
  from
  September 7, 1999
  (Date of Inception)
  to June 30,
  2005
  $ |   | For the
  Year
  Ended
  June 30,
  2005
  $ |            | For the
  Year
  Ended
  June 30,
  2004
  $
|Cash Flows
  From Operating Activities                                          |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Net loss                                                                        |  |  | (6,702,729                                                                            | ) |                                              | (6,301,451 | )                                            |  | (9,204 | )
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Adjustments to reconcile net loss to net
  cash used in operating activities:   |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Amortization                                                                    |  |  | 6,298                                                                                 |   |                                              | 4,756      |                                              |  | 493    |  
|Stock-based compensation                                                        |  |  | 4,786,508                                                                             |   |                                              | 4,514,285  |                                              |  |       |  
|Common stock issued for interest                                                |  |  | 32,063                                                                                |   |                                              | 32,063     |                                              |  |       |  
|Common stock issued for services                                                |  |  | 81,250                                                                                |   |                                              | 81,250     |                                              |  |       |  
|Write off of assets                                                             |  |  | 3,568                                                                                 |   |                                              | 924        |                                              |  | 1,312  |  
|Gain on settlement of debt                                                      |  |  | (12,689                                                                               | ) |                                              | (12,689    | )                                            |  |       |  
|Changes in
  operating assets and liabilities                                   |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|(Increase) in prepaid expenses                                                  |  |  | (454,777                                                                              | ) |                                              | (454,777   | )                                            |  |       |  
|(Increase) in other assets                                                      |  |  | (14,512                                                                               | ) |                                              | (14,512    | )                                            |  | 411    |  
|Increase in deferred revenue                                                    |  |  | 67,000                                                                                |   |                                              | 67,000     |                                              |  |       |  
|Decrease in due to related party                                                |  |  | 12,822                                                                                |   |                                              | 470        |                                              |  | 7,684  |  
|(Increase) in advances and receivables                                          |  |  | (57,265                                                                               | ) |                                              | (57,265    | )                                            |  |       |  
|Increase in accounts payable and accrued
  liabilities                          |  |  | 207,661                                                                               |   |                                              | 198,206    |                                              |  | (1,366 | )
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Net Cash
  (Used In) Operating Activities                                       |  |  | (2,044,802                                                                            | ) |                                              | (1,941,740 | )                                            |  | (670   | )
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Cash Flows
  To Investing Activities                                            |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Purchase of property and equipment                                              |  |  | (27,987                                                                               | ) |                                              | (25,521    | )                                            |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Net Cash To
  Investing Activities                                              |  |  | (27,987                                                                               | ) |                                              | (25,521    | )                                            |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Cash Flows
  From Financing Activities                                          |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Proceeds from the sale of common stock                                          |  |  | 106,220                                                                               |   |                                              |           |                                              |  |       |  
|Proceeds from notes payable                                                     |  |  | 2,321,016                                                                             |   |                                              | 2,321,016  |                                              |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Net Cash
  Provided By Financing Activities                                     |  |  | 2,427,236                                                                             |   |                                              | 2,321,016  |                                              |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Effect of
  Exchange Rate Changes on Cash                                       |  |  | (6,037                                                                                | ) |                                              | (6,037     | )                                            |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Increase
  (Decrease) in Cash                                                   |  |  | 348,410                                                                               |   |                                              | 347,718    |                                              |  | (670   | )
|Cash 
  Beginning of Period                                                    |  |  |                                                                                      |   |                                              | 692        |                                              |  | 1,362  |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Cash  End
  of Period                                                          |  |  | 348,410                                                                               |   |                                              | 348,410    |                                              |  | 692    |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Non-Cash
  Financing Activities                                                 |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Common stock issued in settlement of
  advances                                 |  |  | 133                                                                                   |   |                                              |           |                                              |  |       |  
|Common stock issued for mining claims                                           |  |  | 2,644                                                                                 |   |                                              |           |                                              |  |       |  
|Common stock issued for services                                                |  |  | 372,223                                                                               |   |                                              | 100,000    |                                              |  |       |  
|Common stock issued for settlement of notes
  payable and accrued interest, net |  |  | 1,687,925                                                                             |   |                                              | 1,687,925  |                                              |  |       |  
|Common stock issued for property &
  equipment                                  |  |  | 4,000                                                                                 |   |                                              | 4,000      |                                              |  |       |  
|Warrants issued for financing services                                          |  |  | 662,440                                                                               |   |                                              | 662,440    |                                              |  |       |  
|Capital lease obligation recognized for
  assets under capital lease            |  |  | 10,520                                                                                |   |                                              | 10,520     |                                              |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Supplemental
  Disclosures                                                      |  |  |                                                                                       |   |                                              |            |                                              |  |        |  
|Interest paid                                                                   |  |  |                                                                                      |   |                                              |           |                                              |  |       |  
|Income taxes paid                                                               |  |  |                                                                                      |   |                                              |           |                                              |  |       |  
|                                                                                |  |  |                                                                                       |   |                                              |            |                                              |  |        |  

(The accompanying notes are an integral part
of these consolidated financial statements)

F-4

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Consolidated Statements of Stockholders Equity (Deficit)For the Period from September 7, 1999 (Date of Inception) to
June 30, 2005
(expressed in U.S. dollars)

|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|---------------------------------------------------------------------------------------------------------------------------------- |  | -------------------------- | ----------- | ---------- |  | -------------------------------- | - |  | --------------------------------------------------- | ---------------------------------------------------------------- |  | --------- | - |  | ---------- | - |  | ---------- | -
|                                                                                                                                   |  |                            |             |            |  | Additional 
  Paid-InCapital
  $ |   |  | Accumulated
  
  Other 
  Comprehensive 
  Loss
  $ | Deficit 
  Accumulated 
  During the 
  Development 
  Stage
  $ |  | Total
  $ |  
|                                                                                                                                   |  | Common
  Stock (Note 9(g)) |             |            |  |                                  |  
|                                                                                                                                   |  |                            |             |            |  |                                  |  
|                                                                                                                                   |  | Number
  #                 |             | Amount
  $ |  |                                  |   |  |                                                    
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |  
|Balance  September 7, 1999 (Date of Inception)                                                                                    |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  |           |   |  |           |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Issuance of common stock for services, mining claims and payment of
  advances at $.011 per share                                  |  |                            | 37,500,000  |            |  | 375                              |   |  | 274,625                                             |                                                                  |  |          |   |  |           |   |  | 275,000    |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Net loss                                                                                                                           |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  | (294,522   | ) |  | (294,522   | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Balance  June 30, 2000                                                                                                            |  |                            | 37,500,000  |            |  | 375                              |   |  | 274,625                                             |                                                                  |  |           |   |  | (294,522   | ) |  | (19,522    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Issuance of common stock for cash at $0.02 per share                                                                               |  |                            | 7,966,500   |            |  | 80                               |   |  | 106,140                                             |                                                                  |  |          |   |  |           |   |  | 106,220    |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Net loss                                                                                                                           |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  | (38,069    | ) |  | (38,069    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Balance  June 30, 2001                                                                                                            |  |                            | 45,466,500  |            |  | 455                              |   |  | 380,765                                             |                                                                  |  |           |   |  | (332,591   | ) |  | 48,629     |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Net loss                                                                                                                           |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  | (41,281    | ) |  | (41,281    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Balance  June 30, 2002                                                                                                            |  |                            | 45,466,500  |            |  | 455                              |   |  | 380,765                                             |                                                                  |  |           |   |  | (373,872   | ) |  | 7,348      |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Net loss                                                                                                                           |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  | (18,202    | ) |  | (18,202    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Balance  June 30, 2003                                                                                                            |  |                            | 45,466,500  |            |  | 455                              |   |  | 380,765                                             |                                                                  |  |           |   |  | (392,074   | ) |  | (10,854    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Net loss                                                                                                                           |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  | (9,204     | ) |  | (9,204     | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Balance  June 30, 2004                                                                                                            |  |                            | 45,466,500  |            |  | 455                              |   |  | 380,765                                             |                                                                  |  |          |   |  | (401,278   | ) |  | (20,058    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Return and cancellation of common stock                                                                                            |  |                            | (37,500,000 | )          |  | (375                             | ) |  | 375                                                 |                                                                  |  |          |   |  |           |   |  |           |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Issue of common stock for acquisition of assets from VisualMED
  Clinical Solutions Corporation                                    |  |                            | 31,866,000  |            |  | 319                              |   |  | 3,681                                               |                                                                  |  |          |   |  |           |   |  | 4,000      |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Issue of common stock for settlement of notes payable and accrued
  interest at $0.75 per share, net of financing costs of $18,750 |  |                            | 2,275,567   |            |  | 23                               |   |  | 1,687,902                                           |                                                                  |  |          |   |  |           |   |  | 1,687,925  |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Issue of common stock for services at $2.50 per share                                                                              |  |                            | 40,000      |            |  |                                 |   |  | 100,000                                             |                                                                  |  |          |   |  |           |   |  | 100,000    |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Issue of common stock by exercise of cashless warrants at $0.001 per
  share                                                       |  |                            | 233,333     |            |  | 2                                |   |  | (2                                                  | )                                                                |  |          |   |  |           |   |  |           |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Stock-based compensation                                                                                                           |  |                            |            |            |  |                                 |   |  | 4,514,285                                           |                                                                  |  |          |   |  |           |   |  | 4,514,285  |  
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Foreign currency translation adjustment                                                                                            |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  | (7,171    | ) |  |           |   |  | (7,171     | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Net loss                                                                                                                           |  |                            |            |            |  |                                 |   |  |                                                    |                                                                  |  |          |   |  | (6,301,451 | ) |  | (6,301,451 | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  
|Balance  June 30, 2005                                                                                                            |  |                            | 42,381,400  |            |  | 424                              |   |  | 6,687,006                                           |                                                                  |  | (7,171    | ) |  | (6,702,729 | ) |  | (22,470    | )
|                                                                                                                                   |  |                            |             |            |  |                                  |   |  |                                                     |                                                                  |  |           |   |  |            |   |  |            |  

(The accompanying notes are an integral part
of these consolidated financial statements)

F-5

---



VisualMED Clinical Solutions Corp.(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|1. | Development Stage Company                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   | The Company was
  incorporated in the State of Nevada on September 7, 1999. The Company changed
  its name to VisualMed Clinical Solutions Corporation on November 30, 2004. In
  September 1999 the Company purchased three mineral claims representing
  forty-four units, situated in the Greenwood Mining Division in the Province
  of British Columbia, Canada. The Companys principal business plan was to
  acquire, explore and develop mineral properties and to ultimately seek
  earnings by exploiting the mineral claims. Pursuant to an Agreement dated
  September 23, 2004 (the Agreement), which closed on October 13, 2004, the
  Company agreed to issue 31,866,000 split-adjusted restricted shares of common
  stock to VisualMed Clinical Systems Corporation (VCSC) in exchange for
  certain assets of VCSC consisting of property and equipment and a suite of
  clinical software modules (the modules) that are the key components of a
  Clinical Information System for healthcare facilities. VCSC is a Nevada
  corporation, based in Montreal, Canada, involved in developing software solutions
  targeting clinical medicine and related areas of the healthcare market. The
  Company will have the right to exploit, commercialize, install, support and
  upgrade the modules purchased.  The
  rights to exploit, commercialize, install, support and upgrade are worldwide,
  except for that part of the U.S. market, as well as the Chinese and the
  Japanese language markets, into which VCSC has entered into similar
  agreements with other non-related companies. As a result of the transaction,
  VCSC controlled 80% of the Company. Refer to Note 5.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   | The Companys new business
  plan involves the distribution of medical software, therefore the Company,
  pursuant to the Agreement discussed above, decided to discontinue its mineral
  exploration efforts. These mineral interests will be allowed to lapse. The
  Company is primarily involved in activities related to the distribution of
  medical software and is considered to be a development stage company. Planned
  principal activities have not yet begun. At June 30, 2005, the Company had a
  working capital deficiency of $49,345 and has incurred losses of $6,702,729
  since inception. The ability of the Company to emerge from the development
  stage with respect to any planned principal business activity is dependent
  upon its successful efforts to raise additional equity financing and then
  attain profitable operations. Management has plans to seek additional capital
  through equity and/or debt offerings. There is no guarantee that the Company
  will be able to complete any of the above objectives. These consolidated
  financial statements do not include any adjustments to the recoverability and
  classification of recorded asset amounts and classification of liabilities
  that may be necessary should the Company be unable to continue as a going
  concern. These factors raise substantial doubt regarding the Companys
  ability to continue as a going concern.                                                                                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   | The Company will not be
  able to meet its funding commitments under the Agreement without acquiring
  substantial additional funding in the near future. The Company currently does
  not have sufficient financing arrangements in place to meet its funding
  obligations to VCSC and there is no assurance that the Company will be able
  to acquire the required financing on acceptable terms or at all. The Company
  expects to fund itself by the issue of short-term debt or the sale of common
  shares. Refer to Notes 6 and 13.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|2. | Summary of Significant
  Accounting Principles                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|a) | Basis of Presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   | These consolidated
  financials statements and related notes are presented in accordance with
  accounting principles generally accepted in the United States, and are
  expressed in US dollars. The Company has not produced any revenues from its
  principal business and is a development stage company as defined by Statement
  of Financial Accounting Standard (SFAS) No. 7 Accounting and Reporting by
  Development Stage Enterprises. These financial statements include
  the accounts of the Company and its wholly-owned subsidiary, VisualMed
  Clinical Systems Marketing Inc., a company incorporated and based in Quebec,
  Canada. All intercompany transactions and balances have been eliminated. The
  Companys fiscal year-end is June 30.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|b) | Use of Estimates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   | The preparation of
  financial statements in conformity with U.S. generally accepted accounting
  principles requires management to make estimates and assumptions that affect
  the reported amounts of assets and liabilities and disclosure of contingent
  assets and liabilities at the date of the financial statements and the
  reported amounts of revenues and expenses during the reporting period. Actual
  results could differ from those estimates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

F-6

---



VisualMED Clinical Solutions
Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|2. | Summary of Significant
  Accounting Principles (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|c) | Cash and Cash Equivalents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   | The Company considers all
  highly liquid instruments with a maturity of three months or less at the time
  of issuance to be cash equivalents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|d) | Property and Equipment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   | Property and equipment is
  stated at cost, less accumulated amortization, and consists of office
  furniture, computer hardware and software, leasehold improvements and assets
  under capital lease. Amortization of office furniture is computed using the
  straight-line method over five years. Amortization of computer hardware and
  software is computed using the straight-line method over three years.
  Amortization of leasehold improvements is computed on a straight-line method
  over five years. Amortization of assets under capital lease is computed using
  the straight-line method over the term of the lease.                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|e) | Long-Lived Assets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   | In accordance with SFAS
  No. 144, Accounting for the Impairment or
  Disposal of Long-Lived Assets, the carrying value of intangible
  assets and other long-lived assets is reviewed on a regular basis for the
  existence of facts or circumstances that may suggest impairment. The Company
  recognizes impairment when the sum of the expected undiscounted future cash
  flows is less than the carrying amount of the asset. Impairment losses, if
  any, are measured as the excess of the carrying amount of the asset over its
  estimated fair value.                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|f) | Foreign Currency
  Transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   | The Companys functional
  and reporting currency is the United States dollar. The functional currency
  of the Companys subsidiary is the Canadian dollar. The financial statements
  of the subsidiary are translated to United States dollars in accordance with
  SFAS No. 52 Foreign Currency Translation
  using period-end rates of exchange for assets and liabilities, and average
  rates of exchange for the period for revenues and expenses. Translation gains
  (losses) are recorded in accumulated other comprehensive income (loss) as a
  component of stockholders equity. Foreign currency transaction gains and
  losses are included in current operations.                                                                                                                                                                                                                                                       
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|g) | Development Costs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   | Costs related to the
  enhancement of existing medical software modules are expensed as incurred
  until technological feasibility in the form of a working model has been
  established. The time period between the establishment of technological
  feasibility and completion of product development is expected to be short,
  therefore the Company has not capitalized any product development costs
  during the period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|h) | Basic and Diluted Net
  Income (Loss) Per Share                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   | The Company computes net
  income (loss) per share in accordance with SFAS No. 128, Earnings per Share which requires
  presentation of both basic and diluted earnings per share (EPS) on the face
  of the income statement. Basic EPS is computed by dividing net income (loss)
  available to common shareholders (numerator) by the weighted average number
  of shares outstanding (denominator) during the period. Diluted EPS gives
  effect to all dilutive potential common shares outstanding during the period
  including stock options, using the treasury stock method, and convertible
  preferred stock, using the if-converted method. In computing diluted EPS, the
  average stock price for the period is used in determining the number of
  shares assumed to be purchased from the exercise of stock options or
  warrants. Diluted EPS excludes all dilutive potential shares if their effect
  is anti dilutive.

F-7

---



VisualMED Clinical Solutions
Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|2. | Summary of Significant
  Accounting Principles (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|i) | Financial Instruments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | The carrying value of
  cash, accounts payable, advances to related parties, and notes payable
  approximate fair value due to the relatively short maturity of these
  instruments.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|j) | Revenue Recognition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | The Company has not
  generated any revenues from inception to June 30, 2005. The Company will
  recognize any revenue related to sales of medical software in accordance with
  Statement of Position No. 97-2, Software
  Revenue Recognition (SOP 97-2), as amended by Statement of
  Position No. 98-9, Software Revenue
  Recognition with Respect to Certain Arrangements. Pursuant to SOP
  97-2, revenue will only be recognized when the price is fixed or
  determinable, persuasive evidence of an arrangement exists, the service is
  performed, and collectibility is reasonably assured.  Any allowance for doubtful accounts will
  be based on the Companys detailed assessment of the collectibility of
  specific customer accounts. Any significant customer accounts that are not
  expected to be collected are excluded from revenues. The Company received a
  deposit of $67,000 on a contract entered into to provide product and
  services. As the Company has not provided any product or service to June 30,
  2005, this amount has been recorded as deferred revenue. Incremental direct
  costs related to contract acquisition and origination which result in
  deferred revenue are expensed as incurred.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|k) | Comprehensive Loss                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | SFAS No. 130, Reporting Comprehensive Income,
  establishes standards for the reporting and display of comprehensive loss and
  its components in the financial statements. As at June 30, 2005, the
  Companys only component of comprehensive income (loss) was foreign currency
  translation adjustments.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|l) | Income Taxes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | Potential benefits of
  income tax losses are not recognized in the accounts until realization is
  more likely than not. The Company has adopted SFAS No. 109 Accounting
  for Income Taxes as of its inception. Pursuant to SFAS No. 109
  the Company is required to compute tax asset benefits for net operating
  losses carried forward. Potential benefit of net operating losses have not
  been recognized in these financial statements because the Company cannot be
  assured it is more likely than not it will utilize the net operating losses
  carried forward in future years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|m) | Recent Accounting
  Pronouncements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | In May 2005, the Financial
  Accounting Standards Board (FASB) issued SFAS No. 154, Accounting Changes and Error
  Corrections  A Replacement of APB Opinion No. 20 and SFAS No. 3.
  SFAS 154 changes the requirements for the accounting for and reporting of a
  change in accounting principle and applies to all voluntary changes in
  accounting principle. It also applies to changes required by an accounting
  pronouncement in the unusual instance that the pronouncement does not include
  specific transition provisions. SFAS 154 requires retrospective application
  to prior periods financial statements of changes in accounting principle,
  unless it is impracticable to determine either the period-specific effects or
  the cumulative effect of the change. The provisions of SFAS No. 154 are
  effective for accounting changes and correction of errors made in fiscal
  years beginning after December 15, 2005. The adoption of this standard is not
  expected to have a material effect on the Companys results of operations or
  financial position.                                                                                                                                                     

F-8

---



VisualMED Clinical Solutions
Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|2. | Summary of Significant
  Accounting Principles (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|m) | Recent Accounting
  Pronouncements (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   | In December 2004, the FASB
  issued SFAS No. 153, Exchanges of Nonmonetary Assets - An Amendment of
  APB Opinion No. 29. The guidance in APB Opinion No. 29, Accounting
  for Nonmonetary Transactions, is based on the principle that
  exchanges of nonmonetary assets should be measured based on the fair value of
  the assets exchanged. The guidance in that Opinion, however, included certain
  exceptions to that principle. SFAS No. 153 amends Opinion No. 29 to eliminate
  the exception for nonmonetary exchanges of similar productive assets and
  replaces it with a general exception for exchanges of nonmonetary assets that
  do not have commercial substance. A nonmonetary exchange has commercial
  substance if the future cash flows of the entity are expected to change
  significantly as a result of the exchange. The provisions of SFAS No. 153 are
  effective for nonmonetary asset exchanges occurring in fiscal periods
  beginning after June 15, 2005. Early application is permitted and companies
  must apply the standard prospectively. The adoption of this standard is not
  expected to have a material effect on the Companys results of operations or
  financial position.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   | In December 2004, the FASB
  issued Statement of Financial Accounting Standard (SFAS) No. 123R, Share
  Based Payment. SFAS 123R is a revision of SFAS No. 123 Accounting
  for Stock-Based Compensation, and supersedes APB Opinion No. 25, Accounting
  for Stock Issued to Employees and its related implementation
  guidance. SFAS 123R establishes standards for the accounting for transactions
  in which an entity exchanges its equity instruments for goods or services. It
  also addresses transactions in which an entity incurs liabilities in exchange
  for goods or services that are based on the fair value of the entitys equity
  instruments or that may be settled by the issuance of those equity
  instruments. SFAS 123R focuses primarily on accounting for transactions in
  which an entity obtains employee services in share-based payment
  transactions. SFAS 123R requires a public entity to measure the cost of
  employee services received in exchange for an award of equity instruments
  based on the grant-date fair value of the award (with limited exceptions).
  That cost will be recognized over the period during which an employee is
  required to provide service in exchange for the award  the requisite service
  period (usually the vesting period). SFAS 123R requires that the compensation
  cost relating to share-based payment transactions be recognized in financial
  statements. That cost will be measured based on the fair value of the equity
  or liability instruments issued. Public entities that file as small business
  issuers will be required to apply SFAS 123R in the first interim or annual
  reporting period that begins after December 15, 2005. The adoption of this
  standard is not expected to have a material effect on the Companys results
  of operations or financial position.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   | In March 2005, the SEC
  staff issued Staff Accounting Bulletin No. 107 (SAB 107) to give guidance
  on the implementation of SFAS 123R. The Company will consider SAB 107 during
  implementation of SFAS 123R.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|3. | Advances to Related
  Parties                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

| |                                                                    |  |  |    |   |                     |  |                     |   |  | 
| | ------------------------------------------------------------------ |  |  | -- | - | ------------------- |  | ------------------- | - |  | 
| |                                                                    |  |  |    |   | June 30,
  2005
  $ |  | June 30,
  2004
  $ |  
| |                                                                    |  |  |    |   |                     |  |                     |   |  | 
| | Due from VisualMED
  Clinical Systems Corp., an affiliated company |  |  | (a | ) | 664                 |  |                     |  |  | 
| | Due from VisualMED
  Clinical Systems Inc., an affiliated company  |  |  | (b | ) | 56,601              |  |                     |  |  | 
| |                                                                    |  |  |    |   |                     |  |                     |   |  | 
| |                                                                    |  |  |    |   | 57,265              |  |                     |  |  | 
| |                                                                    |  |  |    |   |                     |  |                     |   |  | 

|   |  |                                                                                                                                                                                                                                              
|-- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|a) |  | The Company is owed $664 from
        its parent company, VisualMed Clinical Systems Corporation (VCSC).
        This amount represents cash advances, is unsecured, non-interest bearing
        and has no specific terms of repayment.  
|   |  |                                                                                                                                                                                                                                              
|b) |  | The Company is owed $56,601
        from VisualMED Clinical Systems Inc., a wholly-owned subsidiary of VCSC.
        This amount represents cash advances, is unsecured, non-interest bearing
        and has no specific terms of repayment.
|   |  |                                                                                                                                                                                                                                              

F-9

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                         
|-- | ------------------------
|4. | Property and
  Equipment

| |                          |  |          |        |                                |  |                                        |  |                                        |  |        |  |  |  |     |  | 
| | ------------------------ |  | -------- | ------ | ------------------------------ |  | -------------------------------------- |  | -------------------------------------- |  | ------ |  |  |  | --- |  | 
| |                          |  | Cost
  $ |        | Accumulated
  Amortization
  $ |  | June 30, 2005
  Net carrying value
  $ |  | June 30, 2004
  Net carrying value
  $ | 
| |                          |  |          |        |                                |  |                                        |  |                                        |  |        |  |  |  |     |  | 
| | Computer
  hardware      |  |          | 9,787  |                                |  | 1,373                                  |  |                                        |  | 8,414  |  |  |  |    |  | 
| | Computer
  software      |  |          | 8,344  |                                |  | 1,821                                  |  |                                        |  | 6,523  |  |  |  |    |  | 
| | Office
  furniture       |  |          | 11,390 |                                |  | 736                                    |  |                                        |  | 10,654 |  |  |  | 924 |  | 
| | Leasehold
  improvements |  |          | 8,673  |                                |  | 874                                    |  |                                        |  | 7,799  |  |  |  |    |  | 
| |                          |  |          |        |                                |  |                                        |  |                                        |  |        |  |  |  |     |  | 
| |                          |  |          | 38,194 |                                |  | 4,804                                  |  |                                        |  | 33,390 |  |  |  | 924 |  | 
| |                          |  |          |        |                                |  |                                        |  |                                        |  |        |  |  |  |     |  | 

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   | Assets under
  capital lease are included in office furniture with a cost of $10,520. During
  the year ended June 30, 2005, the Company recognized amortization of assets
  under capital lease of $649 (June 30, 2004  $nil).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|5. | Asset
  Acquisition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | Pursuant to
  an Agreement dated September 23, 2004, which closed on October 13, 2004, the
  Company issued 31,866,000 split-adjusted restricted shares of common stock to
  VisualMed Clinical Systems Corporation (VCSC) in exchange for certain
  assets of VCSC consisting of property and equipment, a suite of clinical
  software modules that are the key components of a Clinical Information System
  for healthcare facilities, all the issued and outstanding common shares of
  VisualMed Marketing Inc., and other assets.                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | The Company
  completed the Agreement by:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   | i)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | completing a
  private placement of a minimum of $1,500,000 and a maximum of $4,000,000
  within 90 days following the closing of the Agreement (subsequently extended
  to 180 days following the closing of the Agreement). The terms of the private
  placement consisted of a minimum of 2,000,000 units and a maximum of
  5,333,333 units at a price of $0.75 per unit. Each unit consists of one share
  of common stock and one warrant. Each warrant entitles the holder to acquire
  an additional share at a price of $1.25 per share for a period up to two
  years from the closing date of the private placement. The Company completed
  the private placement on March 23, 2005 by the issue of 2,275,567 units at
  $0.75 per unit to settle outstanding notes payable of $1,674,612 and accrued
  interest of $32,063;
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   | ii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | assuming and
  paying up to $100,000 per month towards the ongoing operating costs of VCSC
  which were reimbursed to the Company from the proceeds of the private
  placement;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   | iii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | assuming up
  to a maximum of CDN$304,000, incurred by VCSC from July 1, 2004 to closing of
  the Agreement, to maintain the ongoing operating costs of VCSC which were
  repaid on the closing of the private placement;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   | iv)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | returning to
  treasury and cancelling 37,500,000 split-adjusted common shares, previously
  issued to two former directors of the Company, for no consideration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | The 37,500,000
  split-adjusted shares previously owned by two directors were cancelled and
  the 31,866,000 split-adjusted restricted shares of common stock were issued
  to VCSC.  As a result of the above
  transactions VCSC controlled 80% of the outstanding common shares of the
  Company. The acquisition has been accounted for as an asset purchase in
  accordance with EITF 98-3 Determining Whether a Nonmonetary Transaction
  Involves Receipt of Productive Assets or of a Business, as all but a de
  minimis amount of the fair value of the transferred assets is represented by
  the software modules. These modules must be modified before implementation by
  any potential customers. There were no prior sales by VCSC related to these modules.
  The transferred assets have been recorded at the book value of the
  transferor, VCSC, as this is a related party transaction. Acquisition costs
  of $13,000 associated with this acquisition have been expensed.

| |                                                                    |  |   |       | 
| | ------------------------------------------------------------------ |  | - | ----- | 
| |                                                                    |  | $ |      
| |                                                                    |  |   |       | 
| | Property and equipment                                             |  |   | 4,000 | 
| | Software modules                                                   |  |   |      | 
| | Common shares of VisualMed
  Marketing, Inc. (an inactive company) |  |   |      | 
| |                                                                    |  |   |       | 
| | Paid by the issue of
  31,866,000 split-adjusted common shares     |  |   | 4,000 | 
| |                                                                    |  |   |       | 

F-10

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                                                                                                                                                                                                                                                                                                                               
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|6. | Notes
  Payable                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                               
|   | In addition
  to the notes payable issued as described in Note 5(i), the Company issued
  notes payable for cash proceeds of $646,405, which remain outstanding and
  which bear interest at 10% per annum. These amounts are unsecured, and are
  repayable on demand. At June 30, 2005, interest of $5,460 has been accrued.
|   |                                                                                                                                                                                                                                                                                                                               
|7. | Capital
  Lease Obligation                                                                                                                                                                                                                                                                                                    
|   |                                                                                                                                                                                                                                                                                                                               
|   | During the
  year ended June 30, 2005, the Company entered into a leasing arrangement
  involving office furniture and equipment. The lease is for a three year term
  and requires monthly payments of $340 (CDN $417) per month.                                                                                            
|   |                                                                                                                                                                                                                                                                                                                               
|   | The
  following represents future minimum lease payments under capital leases and
  the present value of the minimum lease payments as of June 30, 2005.                                                                                                                                                                      

| |                                                       |  | $ |       
| | ----------------------------------------------------- |  | - | ------
| |                                                       |  |   | $     
| |                                                       |  |   |       
| | 2006                                                  |  |   | 4,073 
| | 2007                                                  |  |   | 4,073 
| | 2008                                                  |  |   | 3,055 
| |                                                       |  |   |       
| | Total
  minimum lease payments                        |  |   | 11,201
| | Less:
  Amounts representing interest                 |  |   | (1,442
| |                                                       |  |   |       
| | Present
  value of net minimum lease payments         |  |   | 9,759 
| | Current
  portion of obligations under capital leases |  |   | (3,244
| |                                                       |  |   |       
| | Long-term
  obligations under capital leases          |  |   | 6,515 
| |                                                       |  |   |       

|   |                                                                                                                                                                                                                                                                                                                                                                            
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|8. | Related Party
  Transactions/Balances                                                                                                                                                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                            
|a) | The Company
  is indebted to a director and an officer for $9,230, representing expenses
  incurred on behalf of the Company.
  These amounts are included in accounts payable and are unsecured,
  non-interest bearing and have no specific terms of repayment.                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                            
|b) | The Company
  is owed $664 from its parent company, VisualMed Clinical Systems Corporation
  (VCSC).  The Company is owed $56,601
  from VisualMED Clinical Systems Inc., a wholly-owned subsidiary of VCSC.
  These amounts represent cash advances, are unsecured, non-interest bearing
  and have no specific terms of repayment.                                     
|   |                                                                                                                                                                                                                                                                                                                                                                            
|c) | During the
  year ended June 30, 2005, the Company incurred $45,000 in management fees
  paid to its parent company, VisualMed Clinical Systems Corporation (VCSC).                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                            
|d) | At June 30,
  2004, the former President of the Company was owed $12,219 for expenses
  incurred on behalf of the Company. During the year ended June 30, 2005, the
  former President incurred an additional $470 on behalf of the Company. The balance
  owing of $12,689 was forgiven and is included in the statement of operations
  for the year ended June 30, 2005.

F-11

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|9. | Common Stock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|a) | On April 15,
  2005, the Company issued 73,333 split-adjusted shares of common stock upon
  the exercise of 73,333 warrants at $0.001 per share.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|b) | On March 24,
  2005, the Company issued 15,000 split-adjusted shares of common stock at a
  fair value of $37,500 for professional services rendered.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|c) | On March 23,
  2005, the Company issued 25,000 split-adjusted shares of common stock at a
  fair value of $62,500 for consulting services rendered.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|d) | On March 23,
  2005, the Company issued 2,275,567 units at $0.75 per unit for proceeds of
  $1,706,675, consisting of settlement of notes payable of $1,674,612 and
  accrued interest of $32,063, pursuant to a private placement offering. The
  Company incurred financing costs of $18,750 associated with this offering.
  Each unit consisted of one split-adjusted share of common stock and one share
  purchase warrant. Each warrant entitles the holder to acquire one
  split-adjusted share of common stock at $1.25 per share for a period of two
  years.  The fair value of the warrants
  was estimated at $3,851,845 using the Black-Scholes pricing model and is
  included as financing costs on the statement of operations. The following
  assumptions were used: average risk-free interest rate of 3.34%; expected
  life of one year; dividend yield of 0%; and expected volatility of 68%.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|e) | On March 23,
  2005, the Company issued 233,333 warrants as a finders fee pursuant to a
  Finders Fee Agreement dated March 21, 2005. Each warrant entitles the holder
  to acquire one split-adjusted share of common stock at $0.001 per share for a
  period of two years.  The fair value
  of the warrants was estimated at $662,440 using the Black-Scholes pricing model
  and is included as financing costs on the statement of operations. The
  following assumptions were used: average risk-free interest rate of 3.34%;
  expected life of one year; dividend yield of 0%; and expected volatility of
  68%.                                                                                                                                                                                                                                                                                         
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|f) | The Company
  issued 233,333 split-adjusted shares of common stock by the exercise of
  233,333 warrants at $0.001 per share.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|g) | On October
  25, 2004, the Company declared a stock dividend of one additional share of
  common stock for each two shares of common stock outstanding. All per share
  amounts have been retroactively adjusted to reflect the stock dividend.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|h) | On October
  13, 2004, the Company issued 31,866,000 split-adjusted shares of common stock
  at a fair value of $4,000 for the acquisition of certain assets acquired from
  VCSC as described in Note 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|i) | On October
  13, 2004, 37,500,000 split-adjusted shares previously issued to two directors
  of the Company were returned to treasury and cancelled for no consideration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|j) | Share
  Purchase Warrants:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|   | The
  following table summarizes the continuity of the Companys warrants:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

| |                            |  |                    |           |                                           |  |       |  | 
| | -------------------------- |  | ------------------ | --------- | ----------------------------------------- |  | ----- |  | 
| |                            |  | Number of
  Shares |           | Weighted 
  average exercise 
  price
  $ | 
| |                            |  |                    |           |                                           | 
| | Balance, June 30, 2004     |  |                    |          |                                           |  |      |  | 
| | Issued                     |  |                    | 2,508,900 |                                           |  | 1.13  |  | 
| | Exercised                  |  |                    | (233,333  | )                                         |  | 0.001 |  | 
| |                            |  |                    |           |                                           |  |       |  | 
| | Outstanding, June 30, 2005 |  |                    | 2,275,567 |                                           |  | 1.25  |  | 
| |                            |  |                    |           |                                           |  |       |  | 

At
June 30, 2005, the following share purchase warrants were outstanding:

| | Number of 
  Warrants | Exercise 
  Price | Expiry Date   
| | --------------------- | ----------------- | --------------
| |                       |                   |               
| | 2,275,567             | $1.25             | March 23, 2007

F-12

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|10. | Segment
  Disclosures                                                                                                                                                                                                                                                                                                                                                                                                                                           
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|    | The Company
  operates as one operating segment which is the sale of its suite of clinical
  software modules. The Chief Executive Officer is the Companys Chief
  Operating Decision Maker (CODM) as defined by SFAS 131, Disclosure about Segments of an
  Enterprise and Related Information. The CODM allocates resources
  and assesses the performance of the Company based on the results of
  operations.                                            
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|11. | Commitments                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|a)  | In November
  2004, the Company entered into a lease agreement for office premises at a
  rate of $64,100 (CDN$78,700) per annum including property taxes, insurance
  and other operating expenses, for a five year term expiring on September 30,
  2009, with an option to renew for an additional five years. During the year
  ended June 30, 2005, the Company incurred rent expense of $39,055. Future payments
  for the next five years are as follows:

|     |  |   |         | 
|---- |  | - | ------- | 
|2006 |  | $ | 52,400  | 
|2007 |  | $ | 64,100  | 
|2008 |  | $ | 64,100  | 
|2009 |  | $ | 62,100  | 
|2010 |  | $ | 17,500  | 
|     |  |   |         | 
|     |  | $ | 260,200 | 
|     |  |   |         | 

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|b)  | The Company entered into a Finders Fee agreement dated March 21,
  2005, for a term of 90 days. The Company agreed to issue 233,333 warrants as
  a finders fee in payment for the closing of the private placement offering
  of 2,275,567 units described in Note 7(c).
  The warrants have an exercise price of $0.001 per share and expire on
  March 24, 2007.  Upon the exercise of
  warrants by the private placement investors (the Investors), the Company
  will pay a cash fee of 5% of the proceeds to the Finder.  Upon the exercise of the warrants by the
  Investors, the Company will issue a further 166,667 warrants to the Finder,
  or a pro rata amount if less than all warrants issued to the Investors are
  exercised. The Finders warrants are exercisable at $0.001 per share and
  expire on March 24, 2007. The Finder exercised 233,333 warrants to acquire 233,333
  shares of common stock.
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|12. | Income Taxes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|    | At January
  31, 2005, the Company had net operating losses for U.S. federal income tax
  purposes of $1,199,000, which begin expiring in fiscal 2019, and non-capital
  losses for Canadian income tax purposes of $577,000, which begin expiring in
  fiscal 2012. When the future utilization of some portion of the losses
  carried forward is determined not to be more likely than not, a valuation
  allowance is provided to reduce the recorded tax benefits from such assets.
  For the periods ended June 30, 2005 and 2004, the valuation allowance
  established against the deferred tax assets increased by $594,000 and $2,000,
  respectively.                                                                                                                                                                                                                                                                
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|    | A
  reconciliation of the statutory federal income tax rate to the Companys
  effective tax rate follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

| |                                     |         |              
| | ----------------------------------- | ------- | -------------
| |                                     | Canada  | United States
| |                                     |         |              
| | Statutory
  federal income tax rate | 37.6%   | 35.0%        
| | Change in
  valuation allowance     | (37.6%) | (35.0%)      
| |                                     |         |              
| | Total income
  tax expense          |        |             
| |                                     |         |              

F-13

---



VisualMED
Clinical Solutions Corp.
(formerly Ancona Mining Corporation)
(A Development Stage Company)
Notes to the Consolidated Financial Statements 
(expressed in U.S. dollars)

|    |                                                                               
|--- | ------------------------------------------------------------------------------
|12. | Income Taxes
  (continued)                                                    
|    |                                                                               
|    | The deferred
  tax liabilities and assets as at June 30, 2005 were as follows:

| |                                        |            |                  
| | -------------------------------------- | ---------- | -----------------
| |                                        | Canada
  $ | United States
  $
|
| | Deferred tax
  assets                  |            |                  
| | - Net operating losses carried forward | 217,000    | 466,000          
| | - Less valuation allowance             | (217,000)  | (466,000)        
| |                                        |            |                  
| | Net deferred
  tax asset and liability |           |                 
| |                                        |            |                  

| |                                                                               
| | ------------------------------------------------------------------------------
| | The deferred
  tax liabilities and assets as at June 30, 2004 were as follows:

| |                                        |            |                  
| | -------------------------------------- | ---------- | -----------------
| |                                        | Canada
  $ | United States
  $
|
| | Deferred tax
  assets                  |            |                  
| | - Net operating losses carried forward |           | 42,000           
| | - Less valuation allowance             |           | (42,000)         
| |                                        |            |                  
| | Net deferred
  tax asset and liability |           |                 
| |                                        |            |                  

|    |                                                                                                                                                             
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------
|13. | Subsequent
  Events                                                                                                                                         
|    |                                                                                                                                                             
|a)  | On July 19,
  2005, the Company issued 752,230 shares of common stock upon the exercise of
  752,230 warrants at $1.25 per share for proceeds of $940,288.  
|    |                                                                                                                                                             
|b)  | On August
  26, 2005, the Company issued 180,537 shares of common stock upon the exercise
  of 180,537 warrants at $1.25 per share for proceeds of $225,671.

F-14

---



SIGNATURES

Pursuant
  to the requirements of Section 13 or 15(d) of the Securities and Exchange Act
  of 1934, the Registrant has duly caused this amendment to its annual report
  on Form 10-KSB/A to be signed on its behalf by the undersigned, thereunto duly
  authorized, on this 14th day of February 2006.





| | VISUALMED CLINICAL SOLUTIONS CORP.(Registrant)
| | ----------------------------------------------
| | By:                                           
| |                                               

Pursuant
  to the requirements of the Securities Exchange Act of 1934, this report has
  been signed below by the following person on behalf of the Registrant and in
  the capacities.

|Signature              |  | Title                                                                                 |  | Date             
|---------------------- |  | ------------------------------------------------------------------------------------- |  | -----------------
|                       |  |                                                                                       |  |                  
|/s/ Gerard Dab         |  | Principal Executive
        Officer, Secretary and a member of the Board of Directors |  | February 14, 2006
|Gerard Dab            
|                       |  |                                                                                       |  |                  
|                       |  | President, Chief Science
        Officer and a member of the Board of Directors       |  |                  
|Arthur Gelston MD     
|                       |  |                                                                                       |  |                  
|/s/ Philippe Rainville |  | Principal Financial
        Officer, Principal Accounting Officer and Treasurer       |  | February 14, 2006
|Philippe Rainville    
|                       |  |                                                                                       |  |                  
|/s/ Jayne H. Kirby     |  | Vice President of Finance                                                             |  | February 14, 2006
|Jayne H. Kirby        
|                       |  |                                                                                       |  |                  
|/s/ Louis J. Lombardo  |  | A member of the Board
        of Directors                                            |  | February 14, 2006
|Louis J. Lombardo     
|                       |  |                                                                                       |  |                  
|/s/ Philippe Panzini   |  | A member of the Board
        of Directors                                            |  | February 14, 2006
|Philippe Panzini      
|                       |  |                                                                                       |  |                  









---





|Exhibits | Description                                                                                                                                                                       
|-------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|         |                                                                                                                                                                                   
|31.1     | Certification
        of Principal Financial Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
        promulgated under the Securities and Exchange Act of 1934, as amended.
|         |                                                                                                                                                                                   
|31.2     | Certification
        of Principal Executive Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
        promulgated under the Securities and Exchange Act of 1934, as amended.
|         |                                                                                                                                                                                   
|32.1     | Certification
        pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
        of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).                 
|         |                                                                                                                                                                                   
|32.2     | Certification
        pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
        of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).                 









---